Karolinska Development Ab Stock Net Income
| KDEV Stock | SEK 0.28 0.03 9.68% |
As of the 28th of January, Karolinska Development secures the Mean Deviation of 4.42, standard deviation of 8.34, and Risk Adjusted Performance of (0.10). Karolinska Development AB technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices.
Analyzing historical trends in various income statement and balance sheet accounts from Karolinska Development's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Karolinska Development's valuation are summarized below:Karolinska Development AB does not presently have any fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Karolinska |
Karolinska Development 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Karolinska Development's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Karolinska Development.
| 10/30/2025 |
| 01/28/2026 |
If you would invest 0.00 in Karolinska Development on October 30, 2025 and sell it all today you would earn a total of 0.00 from holding Karolinska Development AB or generate 0.0% return on investment in Karolinska Development over 90 days. Karolinska Development is related to or competes with IRLAB Therapeutics, Lipum AB, Isofol Medical, Bio Works, Annexin Pharmaceuticals, Initiator Pharma, and Physitrack PLC. Karolinska Development AB is a venture capital firm specializing in investments in growth capital, seed stage, and early... More
Karolinska Development Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Karolinska Development's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Karolinska Development AB upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.16) | |||
| Maximum Drawdown | 47.86 | |||
| Value At Risk | (13.16) | |||
| Potential Upside | 3.33 |
Karolinska Development Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Karolinska Development's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Karolinska Development's standard deviation. In reality, there are many statistical measures that can use Karolinska Development historical prices to predict the future Karolinska Development's volatility.| Risk Adjusted Performance | (0.10) | |||
| Jensen Alpha | (1.30) | |||
| Total Risk Alpha | (2.07) | |||
| Treynor Ratio | (12.54) |
Karolinska Development January 28, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.10) | |||
| Market Risk Adjusted Performance | (12.53) | |||
| Mean Deviation | 4.42 | |||
| Coefficient Of Variation | (651.77) | |||
| Standard Deviation | 8.34 | |||
| Variance | 69.48 | |||
| Information Ratio | (0.16) | |||
| Jensen Alpha | (1.30) | |||
| Total Risk Alpha | (2.07) | |||
| Treynor Ratio | (12.54) | |||
| Maximum Drawdown | 47.86 | |||
| Value At Risk | (13.16) | |||
| Potential Upside | 3.33 | |||
| Skewness | (1.03) | |||
| Kurtosis | 13.19 |
Karolinska Development Backtested Returns
Karolinska Development has Sharpe Ratio of -0.17, which conveys that the firm had a -0.17 % return per unit of risk over the last 3 months. Karolinska Development exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Karolinska Development's Risk Adjusted Performance of (0.10), standard deviation of 8.34, and Mean Deviation of 4.42 to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 0.1, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Karolinska Development's returns are expected to increase less than the market. However, during the bear market, the loss of holding Karolinska Development is expected to be smaller as well. At this point, Karolinska Development has a negative expected return of -1.47%. Please make sure to verify Karolinska Development's maximum drawdown, potential upside, kurtosis, as well as the relationship between the value at risk and skewness , to decide if Karolinska Development performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.62 |
Good predictability
Karolinska Development AB has good predictability. Overlapping area represents the amount of predictability between Karolinska Development time series from 30th of October 2025 to 14th of December 2025 and 14th of December 2025 to 28th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Karolinska Development price movement. The serial correlation of 0.62 indicates that roughly 62.0% of current Karolinska Development price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.62 | |
| Spearman Rank Test | 0.85 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Karolinska Development AB reported net income of 170.82 M. This is 49.95% lower than that of the Pharmaceuticals sector and 143.87% higher than that of the Health Care industry. The net income for all Sweden stocks is 70.08% higher than that of the company.
Karolinska Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Karolinska Development's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Karolinska Development could also be used in its relative valuation, which is a method of valuing Karolinska Development by comparing valuation metrics of similar companies.Karolinska Development is currently under evaluation in net income category among its peers.
Karolinska Fundamentals
| Return On Equity | -0.11 | |||
| Return On Asset | -0.0168 | |||
| Operating Margin | (14.44) % | |||
| Current Valuation | 247.24 M | |||
| Shares Outstanding | 267.28 M | |||
| Shares Owned By Insiders | 37.17 % | |||
| Shares Owned By Institutions | 5.97 % | |||
| Price To Earning | 7.42 X | |||
| Price To Book | 0.37 X | |||
| Price To Sales | 204.26 X | |||
| Revenue | 2.17 M | |||
| Gross Profit | 2.17 M | |||
| EBITDA | 177.79 M | |||
| Net Income | 170.82 M | |||
| Cash And Equivalents | 42.4 M | |||
| Cash Per Share | 1.85 X | |||
| Debt To Equity | 177.80 % | |||
| Current Ratio | 0.24 X | |||
| Book Value Per Share | 4.56 X | |||
| Cash Flow From Operations | 16.7 M | |||
| Earnings Per Share | 0.86 X | |||
| Target Price | 4.5 | |||
| Beta | 0.4 | |||
| Market Capitalization | 510.26 M | |||
| Total Asset | 1.11 B | |||
| Retained Earnings | (1.85 B) | |||
| Working Capital | 250 M | |||
| Current Asset | 259 M | |||
| Current Liabilities | 9 M | |||
| Z Score | -1.4 | |||
| Net Asset | 1.11 B |
About Karolinska Development Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Karolinska Development AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Karolinska Development using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Karolinska Development AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Karolinska Stock Analysis
When running Karolinska Development's price analysis, check to measure Karolinska Development's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Karolinska Development is operating at the current time. Most of Karolinska Development's value examination focuses on studying past and present price action to predict the probability of Karolinska Development's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Karolinska Development's price. Additionally, you may evaluate how the addition of Karolinska Development to your portfolios can decrease your overall portfolio volatility.